Biotech news continually updated from thousands of sources around the net.
3 hrs ago | Business Wire
89 percent ag... )--Inter Parfums, Inc. today reported results for the fourth quarter ended December 31, 2013.
Trending on the Topix Network
7 hrs ago | WHTC
Teva Pharmaceutical Industries Ltd agreed to pay $27.6 million to settle charges that it paid kickbacks to a Chicago psychiatrist to induce him to prescribe an anti-schizophrenia drug to patients, resulting in more than 100,000 false Medicaid and Medicare claims.
12 hrs ago | ABC News
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc. A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" ... (more)
16 hrs ago | Iol.co.za
US stocks were set for a flat open on Tuesday after a slight decline in the prior session left the S&P 500 within striking distance of its recent record high and amid investor caution as tensions in Ukraine continued.
18 hrs ago | Fox News
When President Bill Clinton announced in 2000 that Craig Venter and Dr. Francis Collins of the National Human Genome Research Institute had succeeded in mapping the human genome, he solemnly declared that the discovery would "revolutionize" the treatment of virtually all human disease.
Medical-device companies have been largely left out of the past year's parade of biotech businesses onto the public markets, yet on Monday two companies selling devices to treat the very same ailment filed their initial public offering paperwork.
La Jolla Pharmaceutical Co said its experimental drug to treat chronic kidney disease met the main goal of improving kidney function in a mid-stage study.
Conversations with clients this week revealed that many investors are also weighing mixed feelings about valuation and the potential for growth.
Discouraging economic news from China and Japan stoked investors' worries about a global slowdown, sending U.S. stocks lower Monday.
Based on the way they are betting their million-dollar-a-year jobs and the firm's capital in multi-million dollar lumps.
ZENBU, a new, freely available bioinformatics tool enables researchers to quickly and easily integrate, visualize and compare large amounts of genomic information resulting from large-scale, next-generation sequencing experiments.
GlaxoSmithKline has lifted its stake in the group's Indian subsidiary to 75 percent, the British drugmaker said on Monday.
Robert W. Baird's target price would indicate a potential downside of 3.97% from the company's current price.
Washington, March 9 : Researchers have now reported their development of new methods and techniques for engineering lungs for patients with COPD and pulmonary fibrosis.
At 46 years old, Zbigniew Kacprzyk thought that he was all set with a career. Punch in, punch out and stow away the nickels for retirement.
Dr. Marcus Plescia, Mecklenburg County's new health director, is following in the footsteps of his grandfather, who was a physician in England, and his uncle, a Catholic priest in Italy who cared for the spiritual needs of infirmed elderly villagers.
Stocks ended mixed Friday, as the enthusiasm following a better-than-expected jobs report wore off.